

B¹
2. (Amended) The method of Claim 1, wherein said vector is administered with a liquid pharmaceutically acceptable carrier.

B²
5. (Amended) The method of Claim 1, wherein said gene of interest comprises a DNA segment encoding a protein operably linked to said promoter operable in gut.

REMARKS

I. In the first full paragraph on page 2 of the Office Action, the Examiner raised an issue with respect to the drawings.

Formal drawings approved in the issued parent are attached hereto.

II. In the second full paragraph on page 2 of the Office Action, the Examiner raised an issue with respect to claim 2. The Examiner believed that the phrase, "vector is administered dissolved or suspended in a liquid" is grammatically improper.

In view of the claim amendment, withdrawal of the rejection is in order.

III. Beginning at the bottom of page 2 of the Office Action, claims 1-6, 8 and 10-12 remain rejected under 35 U.S.C. §112, first paragraph for an alleged want of enablement.

The rejection is traversed for the following reasons.